Published online 18 April 2009
Haematologica, Vol 94, Issue 6, 865-869 doi:10.3324/haematol.2008.004234
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Girodon, F.
Right arrow Articles by Maynadié, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Girodon, F.
Right arrow Articles by Maynadié, M.

Brief Reports

Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study

François Girodon1,2, Gilles Bonicelli1, Céline Schaeffer1, Morgane Mounier2, Serge Carillo3, Ingrid Lafon4, Paule Marie Carli2, Inès Janoray2, Emmanuelle Ferrant4, Marc Maynadié1,2

1 Laboratoire d’Hématologie, Centre Hospitalier Universitaire (CHU) de Dijon
2 Registre des hémopathies malignes de Côte d’Or, EA 4184 Université de Bourgogne, Dijon
3 Laboratoire de Cytologie Clinique et Cytogénétique CHU de Nîmes
4 Service d’Hématologie Clinique, CHU de Dijon, France

Correspondence: François Girodon, Laboratoire d’Hématologie, Hôpital du Bocage, CHU de Dijon, Dijon, France. E-mail:francois.girodon{at}chu-dijon.fr

ABSTRACT

To observe the effect of the new World Health Organization (WHO) criteria on the incidence of myeloproliferative neoplasms, we performed a retrospective study of a population-based registry in the Côte d’Or area, France, from 1980 to 2007. A total of 524 myeloproliferative neoplasms were registered for the 1980–2007 period, including 135 polycythemia vera, 308 essential thrombocythemia and 81 idiopathic myelofibroses. No change in the incidence of either polycythemia vera or idiopathic myelofibrosis was observed for the 2005–2007 period, compared to 1980–2004. On the contrary, a pronounced increase in the incidence of essential thrombocythemia was noted after 2005, mainly due to the use of JAK2 mutation screening and a lower threshold of platelet count. Our study confirms the relevance of the new WHO diagnostic criteria in allowing earlier diagnosis of essential thrombocythemia.

Key words: JAK2 mutation, myeloproliferative neoplasm, polycythemia vera, essential thrombocythemia, incidence.